ClinicalTrials.gg
CompletedNCT04887298Updated Oct 24, 2024

Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

A Phase 1/2 interventional study of Liposomal Annamycin (L-Annamycin) in Sarcoma,Soft Tissue and Pulmonary Metastasis, sponsored by Moleculin Biotech, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Moleculin Biotech, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 244 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
386th of 800
36 · median 35
Started
2021
with 35 others
Phase 1/2
112 of 958
28 open now
Registered
765th of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 386th largest by enrollment of the 800 interventional ones that give a count, is one of 36 that started in 2021, is one of 112 in phase 1/2, and was the 765th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 365 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 301 Sarcoma studies recruiting now, 191 (63%) set no upper age limit and 83 (28%) stop at 75 or younger; 92 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of subjects with STS with lung metastases for which chemotherapy is considered appropriate.

03

Conditions studied

  • Sarcoma,Soft Tissue
  • Pulmonary Metastasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject has a confirmed diagnosis of STS.
  2. The subject must have radiographically in the lung that can be assessed using v.1.1 (defined as the presence of at least one lesion on MRI or CT scan that can be accurately measured with the longest diameter in at least one dimension of ≥10 mm). Subjects with extra-pulmonary disease are eligible.
  3. The subject has documented lung that are considerable eligible for chemotherapy and not eligible for potentially curative surgical resection of pulmonary-only metastatic disease.
  4. The subject had prior therapy for their disease and has shown progression of disease prior to study entry. If the subject received prior anthracycline therapy, they must have received a cumulative dose of ≤ 450 mg/m2.
  5. The subject has an estimated of greater than 3 months.
  6. The subject has an performance status ≤2.
  7. The subject is ≥18 years old at the time of signing .
  8. At least 2 weeks must have passed following treatment for subject's disease with chemotherapy, therapy, targeted agents, biological agents, immune modulators, or radiotherapy.
  9. Any toxicities must have resolved to ≤ grade 1 or previous baseline levels no more than 4 weeks after completing therapy (except alopecia and polyneuropathy).
  10. The subject must have the following adequate laboratory results within 72 hours of starting protocol therapy:

    1. ≥ 1500/mL
    2. count ≥100,000/mL
    3. ≥ 8.0 g/dL
    4. Adequate renal function (The equation will be used to estimate creatinine clearance.

      CrCl (male) = ([140-age] x weight in kg) / (serum creatinine x 72)

      CrCl (female) = ([140-age] x weight in kg) / (serum creatinine x 72) x .85

    5. ≤1.5 x (unless due to Gilbert's syndrome)
    6. (serum glutamic oxaloacetic transaminase) and/or alanine aminotransferase (serum glutamic pyruvic transaminase) ≤ 2.5 × ULN (≤ 5 x ULN in subjects with liver metastases)
  11. The subject is able to understand and sign the informed consent document, can communicate with the Investigator, and can understand and comply with the requirements of the protocol.
  12. All subjects must agree to practice effective during the entire study period and after discontinuing study drug, unless documentation of infertility exists.

    1. Sexually active, fertile women must agree to use 2 effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from the time of informed consent and until at least 6 months after discontinuing study drug
    2. Sexually active men and their sexual partners must agree to use effective contraceptive methods from the time of informed consent until at least 6 months after discontinuing study drug

Exclusion criteria

Exclusion Criteria:

  1. The subject has any uncontrolled intercurrent illness that, in the opinion of the Investigator, would place the subject at unacceptable risk to participate in the study. Examples include, but are not limited to:

    1. Ongoing or active infection
    2. Known positive status for (HIV) or active or C
    3. Cirrhosis
    4. Psychiatric illness/social situations that would limit compliance with study requirements
  2. The subject has any of the following cardiotoxicities:

    1. (LVEF) \<50%
    2. Valvular heart disease
    3. Severe hypertension not controlled by medical therapy
    4. classification of 3 or 4 (Appendix B)
    5. Recent (≤ 6 months) myocardial infarction
    6. Unstable angina
    7. Symptomatic congestive heart failure
    8. Baseline /QTc interval >480 msec
    9. History of additional risk factors for torsade des pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
    10. Use of concomitant medications that significantly prolong the QT/QTc interval
  3. The subject is pregnant (must have negative serum or urine pregnancy test) or lactating.
  4. The subject has a known allergy to study drug, L-Annamycin, or .
  5. The subject is required to use moderate or strong inhibitors and inducers of Cytochrome P450 family enzymes and CYP2B and transporters that cannot be held 3 days before treatment and on the day of treatment (Appendix E).
  6. The subject is unable to comply with the safety monitoring requirements.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Liposomal Annamycin (L-Annamycin)

    Drug: Liposomal Annamycin (L-Annamycin)

Interventions

  • 2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity

    Number of patients with a dose limiting toxicity (DLT) at each dose evaluated

    Time frame: 21 days

Secondary outcomes

  1. Efficacy of L-Annamycin

    Determine preliminary efficacy of L-Annamycin as per revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1)

    Time frame: At the end of every other treatment cycle ( each cycle is 21 days)

  2. Area Under the Plasma Concentration Versus Time Curve (AUC) of L-Annamycin

    Determine pharmacokinetics of L-Annamycin and its metabolite, annamycinol as measured by AUC

    Time frame: Cycle 1 Day 1 ( each cycle is 21 days)

07

Study locations

5 sites
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2022, 15 months.

Of 44 industry-sponsored phase 1/2 interventional studies under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 89. This study's 15 months is below that.

Counting every sponsor, half of 101 studies reached it within 62 months; a quarter within 45 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
May 14, 2021
StartActual
Jun 5, 2021
Primary completionActual
Sep 29, 2022
CompletionActual
Aug 6, 2024
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04887298
Lead sponsor
Moleculin Biotech, Inc.
Responsible party
Sponsor
First posted
May 14, 2021
Start date
Jun 5, 2021
Primary completion
Sep 29, 2022
Completion
Aug 6, 2024
Last update
Oct 24, 2024

Study contacts

Robert Shepard, MD
study director · Moleculin Biotech, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Annamycin

Start the discussion